Section C: AstraZeneca COVID-19 Vaccine Section C: Summary of Changes Version
30
Date
17/12/21
Section
Summary of Changes
Section C
Astra-Zeneca Table colours amended
Pathway to vaccination Section guidance This section is read in conjunction with Pfizer Vaccine section. This section provides additional operational guidance on the AstraZeneca COVID-19 Vaccine vaccination pathway, from booking and scheduling to vaccine preparation onto vaccine administration and observation.
Purpose The purpose of this section is guiding the vaccinating workforce to do the right thing and have the right resources and information available to provide a safe quality vaccination journey for every consumer. The key safety points are: •
Approved for use for people aged 18 years or over
•
AstraZeneca COVID-19 Vaccine does not need to be diluted on site
•
There are 10 doses per vial
The Ministry recommends vaccination to everyone of eligible age in Aotearoa New Zealand. The first line vaccine where there are no contraindications is the Pfizer vaccine. The AstraZeneca vaccine is available as second line vaccine for consumers who meet the eligibility criteria. A prescription from an authorised prescriber is recommended when using the AstraZeneca vaccine as a booster dose or dose 2 of their primary course (i.e., following a non-AstraZeneca COVID-19 vaccine for dose 1), in accordance with Section 25 of The Medicines Act 1981, as it is considered off-label use. Written consent is
Version 30 Page 77
